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context: Genetic and environmental factors are involved in the pathogenesis of type 1 
diabetes mellitus (T1DM), and vitamin D (VD) deficiency appears as a candidate to risk 
factor for developing diabetic kidney disease (DKD).
Objective: The purpose of study was to evaluate the existence of an association 
between low levels of VD and the presence and degree of DKD in T1DM.
Patients and methods: We performed a cross-sectional study, between November 
2014 and December 2015. Levels of 25(OH)D and albuminuria were analyzed in 37 
patients with T1DM and normal glomerular filtration rate. Thirty-six subjects were evalu-
ated as a control group.
results: Patients with T1DM and hypovitaminosis D had higher levels of albuminuria 
compared to those with normal VD levels [albuminuria (log10) = 1.92 vs. 1.44; p < 0.05]. 
When we have separated the group of patients according to stage of DKD in patients 
with normo, micro, and macroalbuminuria, there are lower levels of 25(OH)D in the last 
when compared to the first two groups (26.7 ± 6.2, 24.8 ± 7.0, and 15.9 ± 7.6 ng/ml; 
p < 0.05, respectively). In T1DM group, we have found correlations between VD levels 
and both albuminuria and DKD stages (r = −0.5; p < 0.01 and r = −0.4; p < 0.05, 
respectively). A simple linear regression model, with albuminuria as the dependent vari-
able and VD as an independent variable, showed r2 = 0.2 and p < 0.01.
conclusion: Our data suggest an association between reduced levels of VD and the 
presence and severity of DKD.
Keywords: type 1 diabetes mellitus, albuminuria, vitamin D, 25(Oh)D, diabetic kidney disease
inTrODUcTiOn
Both environmental and genetics have been known as risk factors involved in the pathogenesis of 
type 1 diabetes mellitus (T1DM). The vitamin D (VD) deficiency appears as a candidate to risk factor 
for developing T1DM and diabetic kidney disease (DKD).
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The VD deficiency is associated with increased urinary 
albumin excretion, as well as an increase in the prevalence of car-
diovascular disease and mortality in patients with chronic kidney 
disease in the general population, which has decreased levels of 
this vitamin (1, 2). The great difficulty in assessing relationship 
between low levels of VD and DKD is the fact of renal injury itself 
cause reduced levels of VD. It makes difficult to establish whether 
VD deficiency would be a triggering environmental factor of 
DKD or just a consequence of this progression.
A few studies evaluating VD levels in the early stages of DKD 
and its association with the presence of microalbuminuria have 
found conflicting results (3–5). Therefore, it is important to 
establish the existence of a direct relationship between low levels 
of VD and the presence of DKD in T1DM, particularly in early 
cases, with normal glomerular filtration rate (GFR).
Therefore, the purpose of the present study was to evaluate 
the existence of an association between low VD levels with the 
presence and degree of DKD in T1DM with normal GFR.
MaTerials anD MeThODs
study Design and Patients
We performed a cross-sectional study, between November 
2014 and December 2015, in which levels of 25(OH)D and 
albuminuria were analyzed. Patients were recruited from 
Endocrinology Division of the Federal University of Pará, 
included 37 T1DM with normal GFR (≥90  ml/min/1.73  m2) 
(6) and 36 controls with normal serum creatinine and without 
comorbidities. The control group was recruited in communi-
ties near to University Hospital. Both groups were matched 
by age and GFR. Exclusion criteria were pregnancy, lactation, 
individuals with a history of liver disease, use of VD/calcium in 
the last 6 months, prior concomitant history of metabolic bone 
diseases, hyperthyroidism or hypothyroidism, and patients. 
The study was approved by the University Hospital João de 
Barros Barreto ethics committee – protocol No. 2158/11, and 
it was in accordance with the standards of the National Health 
Council. Informed consent was obtained from all patients for 
being included in the study.
clinical and laboratorial Data
All patients had the following clinical parameters measured: 
weight, height, body mass index (BMI), and systolic and diastolic 
blood pressure. Diabetic patients (group 1) and controls (group 
2) were submitted to the following laboratory tests: glycated 
hemoglobin (HbA1c), serum creatinine, 25(OH)D, TSH, free T4, 
total cholesterol and fractions, triglycerides, and fasting glucose. 
Albuminuria in three 24 h urine samples was measured only in 
T1DM. HbA1c was measured by HPLC. The levels of 25(OH)
D were measured by chemiluminescence immunoassay (7) and 
are classified according to their levels: deficiency (<20  ng/ml), 
insufficiency (20.0–29.9 ng/ml), and normal (≥30.0 ng/ml). The 
GFR was calculated by formula CKD-EPI (8). The DKD was 
graded in stages by albuminuria and GFR. Albuminuria was 
performed by immunoturbidimetry (9), and T1DM was classified 
according to results in normoalbuminuria (<30 mg/g creatinine), 
microalbuminuria (≥30 mg/g creatinine and <300 mg/g creati-
nine), and macroalbuminuria (≥300 mg/g creatinine).
statistical analysis
Categorical variables were described as frequency (percentage), 
numeric variables with normal distribution were described as 
mean (SD), and the other as median (minimum–maximum). 
Chi-square and Fisher tests were used to compare categorical 
variables. The Student’s t-test and Mann–Whitney test were used 
to compare two groups of numerical variables with and without 
normal distribution, respectively. To establish correlations 
between variables, Pearson and Spearman tests were used. The 
ANOVA test compared more than two groups of numerical vari-
ables with normal distribution, and the Kruskal–Wallis test was 
used to compare more than two groups of numerical variables 
without normal distribution.
In regard to DKD, the stage, normoalbuminuria, microalbu-
minuria, and macroalbuminuria, was given as DKD indexes the 
numerals 0, 1, and 2, respectively. Similarly, in regard to VD levels, 
the status, normal, insufficiency, and deficiency, was given as VD 
indexes the numerals 0, 1, and 2, respectively. For clarification, 
the index was used for statistical analysis.
Additionally, albuminuria values were converted to log base 
10 (log10) to better analyze the data. A simple linear regression 
model was analyzed using albuminuria as dependent vari-
able and VD as independent variable. We have also created a 
regression model (backward stepwise) with albuminuria as 
dependent variable and age, sex, BMI, SBP, DBP, 25(OH)D, 
HbA1c, and duration of T1DM to determine the important of 
those variables as independent predictors. After that, another 
multiple linear regression model was used to verify if a com-
bination of the variables selected from the backward stepwise 
model could increase the predictive value to albuminuria when 
compared to the simple linear regression model using only VD 
levels. Interferences were represented by hypothesis test with a 
significance level of 0.05 bilaterally. All information was stored 
and processed using the software Statistical Package for Social 
Sciences (SPSS) 21.0 (IBM).
resUlTs
The clinical and laboratorial characteristics of T1DM and controls 
are shown in Tables 1 and 2, respectively.
There were no differences between T1DM and controls 
in the number of patients at different stages according to VD 
levels (Figure 1). The prevalence of hypovitaminosis D among 
controls was quite high (78%), and there was no difference in 
relation to T1DM, whose prevalence was 73%. For DKD stage, 
it was found that 8 patients (21.6%) had normoalbuminuria, 25 
patients (67.6%) had microalbuminuria, and 4 patients (10.8%) 
had macroalbuminuria. The VD levels in different stages of DKD 
are shown in Table 3.
Patients with T1DM and hypovitaminosis D had higher levels 
of albuminuria compared to those with normal VD levels [albu-
minuria (log10) = 1.92 vs. 1.44; p < 0.05].
A correlation was found between VD and albuminuria (trans-
formed into log10) in T1DM (Figure  2). In addition, we have 
FigUre 1 | status according to VD levels in T1DM and controls.
Table 2 | laboratory characteristics of T1DM and controls.
hba1c (%) Vitamin D (ng/ml) gFr (ml/min/1.73 m2) Microalbuminuria (mg/24 h) Microalbuminuria (log10 mg/24 h)
T1DM (N = 37) 10.3 ± 3.2 24.2 ± 7.4 95 ± 20 236.2 ± 690.7 1.78 ± 0.36
Controls (N = 36) 5.2 ± 0.3 25.8 ± 11.2 92 ± 11 – –
p <0.05 NS NS – –
log10, transformation of microalbuminuria value to log10; GFR, glomerular filtration rate; HbA1c, glycated hemoglobin; NS, not significant.
Table 1 | clinical characteristics of T1DM and controls.
sex (M/F) age (years) DT1DM (years) Pas (mmhg) PaD (mmhg) iMc (kg/m2)
T1DM (N = 37) 13/24 28.6 ± 8.1 13.2 ± 6.6 120.3 ± 13.6 76.1 ± 9.6 24.2 ± 3.9
Controls (N = 36) 19/17 25.2 ± 3.0 – 119.1 ± 12.3 74.0 ± 7.9 26.7 ± 5.8
p NS NS – NS NS <0.05
DT1DM, duration of diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; NS, not significant.











*p < 0.05 vs. normoalbuminuria and microalbuminuria.
FigUre 2 | correlation between vitamin D levels and albuminuria in 
patients with T1DM.
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found a progressive decrease of VD levels as the stage of DKD 
worsened (Figure 3). In addition, albuminuria levels according to 
the status of VD levels had similar behavior (Figure 4).
Our simple linear regression model, with albuminuria as the 
dependent variable and VD as an independent variable, showed 
a r2 = 0.2 and p < 0.01. The β1 coefficient was equal to −43. This 
suggests that every increase of 1 ng/ml of VD could result in a 
reduction of 43 mg/g in albuminuria.
Our backward stepwise regression model has found that VD, 
HbA1c, and duration of T1DM were independent predictors of 
albuminuria. When we have included those three variables in a 
multiple linear regression model, we have found an increase in 
predictive value to albuminuria when compared to 25(OH)D 
alone (r2 = 0.34 and p < 0.01).
DiscUssiOn
Our data suggest an association between reduced levels of VD 
and the presence and severity of DKD in T1DM. There are few 
studies (3–5) assessing VD levels in the early stages of DKD 
and its association with the presence of microalbuminuria with 
conflicting results. Joergensen et al. (4) in 2011, evaluated VD 
as a predictor for progression of normoalbuminuria to micro-
albuminuria in T1DM. To this end, they collected VD before 
the development of microalbuminuria, and these patients were 
followed for about 26  years. In this period, 81% of patients 
developed microalbuminuria, and this was not associated with 
reduced levels of VD. Differently, Verrotti et al. (3) have com-
pared VD levels and urinary albumin excretion in 22 patients 
with T1DM and normoalbuminuria, 24 T1DM and microalbu-
minuria, and 24 controls. Their findings showed lower levels of 
25(OH)D in patients with microalbuminuria when compared to 
other groups. Additionally, de Boer et al. have tested associations 
FigUre 3 | correlation between VD levels and stages of DKD.
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FigUre 4 | correlation between the levels of albuminuria and the status of vitamin D levels in patients with T1DM.
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between circulating VD metabolites and microalbuminuria in 
T1DM. They have found that low plasma concentrations of 
VD (below 20 ng/ml) were associated with an increased risk of 
microalbuminuria in 65% of patients. Our findings reinforce 
the data described by de Boer et al. (5). Although there was no 
difference between the levels of 25(OH)D between T1DM with 
normo and microalbuminuria, we have demonstrated a good 
correlation between the reduction in VD levels and evolution 
of DKD stages.
It has been reported involvement of VD deficiency in the 
development of diabetes (10). However, it is unclear whether 
VD deficiency could be an environmental factor involved in 
the pathophysiology and progression of DKD. The VD recep-
tors (VDRs) are present in the kidney (11). Zhang et al. (12) 
in 2008 has demonstrated that inactivation of the VDR results 
in development of more severe DKD in rats, suggesting a 
renoprotective role of VD against renal injury by regulating 
the renin–angiotensin system and other genes. In their study, 
diabetic rats were separated according to presence or not of 
VDR. After 5  weeks, both groups developed abnormal albu-
minuria; however, this was more precocious and significant in 
the group of animals with absent VDR. In addition, WuWong 
et al. (13) in 2013 demonstrated for the first time that calcitriol 
exhibits a consistent effect on regulating VDR target gene 
expression, and calcidiol appears to have differential effects 
on the expression of different genes. It is not well studied 
whether the prehormones have effects similar to VDR agonists 
in providing cardiovascular benefits and/or improving survival 
in CKD. The VITAL study (14) has showed that treatment for 
24 weeks with 2 μg of paricalcitol (VD analog) in patients with 
type 2 diabetes and DKD results in a reduction on excretion 
of residual albuminuria. In contrast, a reduction has not been 
demonstrated in individuals using 1 μg daily, as well as those on 
placebo. Additionally, it is unclear if an increase of VD levels to 
>30 ng/ml during a long time could help to elucidate whether 
VD have possible therapeutic effect on DKD in early stages. 
Therefore, there are no studies indicating the optimal level of 
VD supplementation.
A possible role of VD in DKD is the loss of VD carrier pro-
teins (BPD). Thrailkill et al. (15) have analyzed the renal loss 
of BPD in diabetic patients and have found an increase in the 
urinary loss of this protein, with a higher increase in patients 
with abnormal albuminuria, suggesting that this mechanism 
could collaborate with hypovitaminosis D. Therefore, the ques-
tion whether the urinary loss of this protein would be a risk 
marker of renal injury or a causal factor could be raised. Our 
regression data points to a VD direct action mechanism on 
urinary albumin excretion independently of diabetic glycemic 
control.
An interesting study design that could evaluate the role of 
VD as an environmental factor of DKD could be cohort study 
in T1DM with normoalbuminuria with evaluation of VD levels 
to observe the development of DKD. However, this would be an 
unethical study, due to the need to replace VD when deficiency 
is detected. The closest way to answer this question would be 
through the treatment of T1DM with newly diagnosed microal-
buminuria, even in the absence of VD deficiency, in an attempt to 
maintain VD levels above 30 ng/ml and follow the progression of 
DKD. If this hypothesis is confirmed, a major step would be taken 
with the use of VD in these cases.
In our study, the prevalence of VD deficiency in T1DM 
was not different from controls. Pozzilli et al. (16) have dem-
onstrated high VD deficiency rates in patients with newly 
diagnosed T1DM when compared to controls on a sunny town 
of Italy in the Lazio region. At the same time, Feng et al. (17) 
in 2015 conducted a meta-analysis reviewing 13 articles with 
a total sample of 3494 participants (1790 healthy controls and 
1704 with T1DM) and have confirmed the previous data. In 
this meta-analysis, 25(OH)D levels in T1DM were 2.61 ng/ml 
lower than controls. Our control group have presented higher 
BMI when compared to T1DM. It has been reported that excess 
weight is associated with VD deficiency (18), so it could justify 
in part the fact that we have found no differences in VD levels 
between the two groups.
Currently, we have no large studies to determine the preva-
lence of VD deficiency in Brazil. Data from the city of Recife 
indicate low levels of VD in postmenopausal women (43%) (10), 
while Linhares et  al. (19) evaluating 226 children of the same 
population and geographic region have found no VD deficiency. 
In contrast, in a study with 102 holmes for the elderly in Porto 
Alegre, where the weather is less sunny, the prevalence of VD 
deficiency was considerably higher (87.5%) (20). Our region is 
warm, humid, and sunny; however, our population has the habit 
to protect yourself from the sun. These factors may have influ-
enced our results and led to a high prevalence of VD deficiency 
in controls.
Among the weaknesses of our study is the low number of 
patients with normoalbuminuria when compared to those with 
microalbuminuria. This fact, associated with the great variability 
of albuminuria in T1DM, could have been responsible for no 
differences between VD levels in these two groups. The number 
of patients with macroalbuminuria also need to be increased. But, 
the last problem is more difficult to resolve because this kind of 
patients in general are not in early stages of DKD and do not have 
normal GFR.
The clinical applicability of our study would be to establish 
an association between VD levels and DKD in early stages, but 
the number of patients must be increased. Prospective studies are 
necessary to establish whether the replacement or supplementa-
tion of VD could be useful in the treatment of diabetes kidney 
disease in T1DM.
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